

# Kristina M Brooks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4231040/publications.pdf>

Version: 2024-02-01

33  
papers

1,106  
citations

567281  
15  
h-index

414414  
32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2149  
citing authors

#	ARTICLE	IF	CITATIONS
1	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation, 2018, 128, 3041-3052.	8.2	387
2	National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain. Journal of the American College of Radiology, 2016, 13, 237-241.	1.8	96
3	Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clinical Pharmacology and Therapeutics, 2018, 104, 364-373.	4.7	93
4	Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. Open Forum Infectious Diseases, 2017, 4, ofx202.	0.9	56
5	Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clinical Infectious Diseases, 2018, 67, 193-201.	5.8	49
6	Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	42
7	Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?. Pharmacotherapy, 2019, 39, 576-598.	2.6	41
8	Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention. Clinical Pharmacology and Therapeutics, 2018, 104, 1056-1059.	4.7	29
9	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clinical Pharmacology and Therapeutics, 2021, 110, 36-48.	4.7	29
10	Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 333-342.	3.3	28
11	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 323-330.	2.1	26
12	Pharmacotherapy Challenges of Fontan-Associated Plastic Bronchitis: A Rare Pediatric Disease. Pharmacotherapy, 2013, 33, 922-934.	2.6	21
13	Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 565-573.	2.3	20
14	Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers. Circulation, 2016, 134, 1909-1911.	1.6	18
15	Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza A M1/M2 translation. British Journal of Clinical Pharmacology, 2018, 84, 25-34.	2.4	17
16	Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products. Expert Review of Clinical Pharmacology, 2017, 10, 59-79.	3.1	15
17	Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. Aids, 2021, 35, 407-417.	2.2	15
18	Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infectious Diseases, 2021, 8, ofaa564.	0.9	14

#	ARTICLE	IF	CITATIONS
19	Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2360-2364.	3.0	13
20	Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy Tube Administration. <i>Pharmacotherapy</i> , 2017, 37, e82-e89.	2.6	12
21	Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 835-837.	1.1	12
22	Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 421-428.	1.1	12
23	Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery. <i>Journal of the Endocrine Society</i> , 2017, 1, 994-1001.	0.2	9
24	Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2352-2359.	3.0	9
25	Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3303-3310.	3.0	9
26	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487.	2.2	8
27	The role of jab1, a putative downstream effector of the neurotrophic cytokine macrophage migration inhibitory factor (MIF) in zebrafish inner ear hair cell development. <i>Experimental Neurology</i> , 2018, 301, 100-109.	4.1	6
28	Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 173-180.	2.1	6
29	Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 332-339.	2.0	5
30	A Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the Lungs. <i>Pharmaceutical Research</i> , 2016, 33, 72-82.	3.5	4
31	Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 343-350.	2.1	3
32	The use of technology-based adherence monitoring in the treatment of hepatitis C virus. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210956.	1.8	2
33	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	0